ReviewPediatric pulmonology2022
Increasing life expectancy in cystic fibrosis: Advances and challenges.
Review in Pediatric pulmonology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania.Children (Basel, Switzerland) · 2026Article
- Impact of Highly Effective CFTR Modulator Therapy on Physical Activity, Sleep, and Sinonasal Symptoms in Preschool Children with Cystic Fibrosis: A Prospective Single-Center Pilot Study.Advances in respiratory medicine · 2026Observational
- Deep Optic Nerve Head Structural Alterations in Adults with Cystic Fibrosis.Journal of clinical medicine · 2026Article
- Inhalable gene and RNA therapy for cystic fibrosis: perspectives and progress in clinical development.Nanomedicine (London, England) · 2026Review
- Age-Dependent Systemic Regulation of C1q/TNF-Related Protein 3 and Progranulin in Patients with Cystic Fibrosis: Biomarkers or Therapeutic Targets?Biomedicines · 2026Article
- Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.BMC microbiology · 2026Article
- Cholinergic signaling modulates intestinal pathophysiology in a Drosophila model of cystic fibrosis.PLoS genetics · 2026Article
- Antibiotic resistance of Pseudomonas aeruginosa strains-intracellular metabolomics analysis.The Journal of antimicrobial chemotherapy · 2026Article
- Review
- Image quality in ultra-low-dose chest CT versus chest x-rays guiding paediatric cystic fibrosis care.European radiology · 2026Article
- Evolving Cystic Fibrosis Care: Lung Immunology and Emerging Health Challenges in the Era of CFTR Modulators.Biomolecules · 2025Review
- Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.Pulmonary therapy · 2025Review
- Article
- The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.Microbiology (Reading, England) · 2025Review
- Anesthetic Management and Considerations for Cesarean Delivery in a Patient With Cystic Fibrosis.Case reports in anesthesiology · 2025Article
- A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?Journal of clinical medicine · 2024Review
- Testosterone concentrations and associated predictors in men with cystic fibrosis: A retrospective, single-center study.The American journal of the medical sciences · 2024Article
- Olfactory loss in people with cystic fibrosis: Community perceptions and impact.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Development of a Miniaturized Mechanoacoustic Sensor for Continuous, Objective Cough Detection, Characterization and Physiologic Monitoring in Children With Cystic Fibrosis.IEEE journal of biomedical and health informatics · 2024Article
- TRPV4 Channel Modulators as Potential Drug Candidates for Cystic Fibrosis.International journal of molecular sciences · 2024Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.